Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma

High-dose interleukin-2 (HD IL-2) was approved for treatment of metastatic renal cell carcinoma (mRCC) in 1992 and for metastatic melanoma (mM) in 1998, in an era predating targeted therapies and immune checkpoint inhibitors. The PROCLAIMSM registry was established to collect and analyze data for pa...

Full description

Bibliographic Details
Main Authors: Alva, Ajjai, Daniels, Gregory A., Wong, Michael K. K., Kaufman, Howard L., Morse, Michael A., McDermott, David F., Clark, Joseph I., Agarwala, Sanjiv S., Miletello, Gerald, Logan, Theodore F., Hauke, Ralph J., Curti, Brendan, Kirkwood, John M., Gonzalez, Rene, Amin, Asim, Fishman, Mayer, Agarwal, Neeraj, Lowder, James N., Hua, Hong, Aung, Sandra, Dutcher, Janice P.
Format: Online
Language:English
Published: Springer Berlin Heidelberg 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099373/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099373/

Similar Items